Adrenal medulla and Parkinson's disease

S. L. Stoddard, G. J. Merkel, J. A. Cook, A. R. Zinsmeister, S. W. Carmichael

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Parkinson's disease has been described as a multisystem disorder that includes alterations in the function of the autonomic nervous system. The activity of the adrenal medulla in this disease has not been thoroughly investigated. Previous reports are reviewed that demonstrate that the adrenal medullae of parkinsonian patients are compromised, having a decreased content of all catecholamines and several neuropeptides. An animal model was used to investigate whether the observations made in human patients were related to extended treatment with antiparkinsonian medications or were a natural concomitant of the disease. Administration of L-dopa and/or carbidopa to C57BL mice for 4-16 weeks had no significant effect on the level of any of the adrenal medullary catecholamines. Treatment with MPTP 4-16 weeks prior to sacrifice did not deplete adrenal medullary catecholamines in these animals, thus not fully mimicking Parkinson's disease in this animal model. The only significant effect was an interaction between group (MPTP or control) and treatment with antiparkinsonian medications; L-dopa, in the absence and presence of carbidopa, had opposite effects in the two groups. Based primarily on the lack of effect of antiparkinsonian medications on adrenal medullary catecholamines, it was concluded that the adrenal medullary depletion observed in human patients was a peripheral concomitant of Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)151-154
Number of pages4
JournalMicroscopy Research and Technique
Volume29
Issue number2
StatePublished - 1994

Fingerprint

catecholamine
Parkinson disease
adrenal medulla
Adrenal Medulla
catecholamines
Antiparkinson Agents
Catecholamines
Parkinson Disease
dopa
Carbidopa
drug therapy
L-dopa
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
animal models
Levodopa
Animals
autonomic nervous system
Animal Models
disease models
Autonomic Nervous System

Keywords

  • Antiparkinsonian medication
  • Catecholamines
  • Human
  • Mouse
  • MPTP

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Anatomy
  • Instrumentation

Cite this

Stoddard, S. L., Merkel, G. J., Cook, J. A., Zinsmeister, A. R., & Carmichael, S. W. (1994). Adrenal medulla and Parkinson's disease. Microscopy Research and Technique, 29(2), 151-154.

Adrenal medulla and Parkinson's disease. / Stoddard, S. L.; Merkel, G. J.; Cook, J. A.; Zinsmeister, A. R.; Carmichael, S. W.

In: Microscopy Research and Technique, Vol. 29, No. 2, 1994, p. 151-154.

Research output: Contribution to journalArticle

Stoddard, SL, Merkel, GJ, Cook, JA, Zinsmeister, AR & Carmichael, SW 1994, 'Adrenal medulla and Parkinson's disease', Microscopy Research and Technique, vol. 29, no. 2, pp. 151-154.
Stoddard SL, Merkel GJ, Cook JA, Zinsmeister AR, Carmichael SW. Adrenal medulla and Parkinson's disease. Microscopy Research and Technique. 1994;29(2):151-154.
Stoddard, S. L. ; Merkel, G. J. ; Cook, J. A. ; Zinsmeister, A. R. ; Carmichael, S. W. / Adrenal medulla and Parkinson's disease. In: Microscopy Research and Technique. 1994 ; Vol. 29, No. 2. pp. 151-154.
@article{eafca9caf6a145a1b3ac4696e70da364,
title = "Adrenal medulla and Parkinson's disease",
abstract = "Parkinson's disease has been described as a multisystem disorder that includes alterations in the function of the autonomic nervous system. The activity of the adrenal medulla in this disease has not been thoroughly investigated. Previous reports are reviewed that demonstrate that the adrenal medullae of parkinsonian patients are compromised, having a decreased content of all catecholamines and several neuropeptides. An animal model was used to investigate whether the observations made in human patients were related to extended treatment with antiparkinsonian medications or were a natural concomitant of the disease. Administration of L-dopa and/or carbidopa to C57BL mice for 4-16 weeks had no significant effect on the level of any of the adrenal medullary catecholamines. Treatment with MPTP 4-16 weeks prior to sacrifice did not deplete adrenal medullary catecholamines in these animals, thus not fully mimicking Parkinson's disease in this animal model. The only significant effect was an interaction between group (MPTP or control) and treatment with antiparkinsonian medications; L-dopa, in the absence and presence of carbidopa, had opposite effects in the two groups. Based primarily on the lack of effect of antiparkinsonian medications on adrenal medullary catecholamines, it was concluded that the adrenal medullary depletion observed in human patients was a peripheral concomitant of Parkinson's disease.",
keywords = "Antiparkinsonian medication, Catecholamines, Human, Mouse, MPTP",
author = "Stoddard, {S. L.} and Merkel, {G. J.} and Cook, {J. A.} and Zinsmeister, {A. R.} and Carmichael, {S. W.}",
year = "1994",
language = "English (US)",
volume = "29",
pages = "151--154",
journal = "Microscopy Research and Technique",
issn = "1059-910X",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Adrenal medulla and Parkinson's disease

AU - Stoddard, S. L.

AU - Merkel, G. J.

AU - Cook, J. A.

AU - Zinsmeister, A. R.

AU - Carmichael, S. W.

PY - 1994

Y1 - 1994

N2 - Parkinson's disease has been described as a multisystem disorder that includes alterations in the function of the autonomic nervous system. The activity of the adrenal medulla in this disease has not been thoroughly investigated. Previous reports are reviewed that demonstrate that the adrenal medullae of parkinsonian patients are compromised, having a decreased content of all catecholamines and several neuropeptides. An animal model was used to investigate whether the observations made in human patients were related to extended treatment with antiparkinsonian medications or were a natural concomitant of the disease. Administration of L-dopa and/or carbidopa to C57BL mice for 4-16 weeks had no significant effect on the level of any of the adrenal medullary catecholamines. Treatment with MPTP 4-16 weeks prior to sacrifice did not deplete adrenal medullary catecholamines in these animals, thus not fully mimicking Parkinson's disease in this animal model. The only significant effect was an interaction between group (MPTP or control) and treatment with antiparkinsonian medications; L-dopa, in the absence and presence of carbidopa, had opposite effects in the two groups. Based primarily on the lack of effect of antiparkinsonian medications on adrenal medullary catecholamines, it was concluded that the adrenal medullary depletion observed in human patients was a peripheral concomitant of Parkinson's disease.

AB - Parkinson's disease has been described as a multisystem disorder that includes alterations in the function of the autonomic nervous system. The activity of the adrenal medulla in this disease has not been thoroughly investigated. Previous reports are reviewed that demonstrate that the adrenal medullae of parkinsonian patients are compromised, having a decreased content of all catecholamines and several neuropeptides. An animal model was used to investigate whether the observations made in human patients were related to extended treatment with antiparkinsonian medications or were a natural concomitant of the disease. Administration of L-dopa and/or carbidopa to C57BL mice for 4-16 weeks had no significant effect on the level of any of the adrenal medullary catecholamines. Treatment with MPTP 4-16 weeks prior to sacrifice did not deplete adrenal medullary catecholamines in these animals, thus not fully mimicking Parkinson's disease in this animal model. The only significant effect was an interaction between group (MPTP or control) and treatment with antiparkinsonian medications; L-dopa, in the absence and presence of carbidopa, had opposite effects in the two groups. Based primarily on the lack of effect of antiparkinsonian medications on adrenal medullary catecholamines, it was concluded that the adrenal medullary depletion observed in human patients was a peripheral concomitant of Parkinson's disease.

KW - Antiparkinsonian medication

KW - Catecholamines

KW - Human

KW - Mouse

KW - MPTP

UR - http://www.scopus.com/inward/record.url?scp=0028109109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028109109&partnerID=8YFLogxK

M3 - Article

C2 - 7812036

AN - SCOPUS:0028109109

VL - 29

SP - 151

EP - 154

JO - Microscopy Research and Technique

JF - Microscopy Research and Technique

SN - 1059-910X

IS - 2

ER -